文献速递肿瘤 PET/CT核素与放射性配体治疗

靶向CAIX的诊疗配对[68Ga]Ga/[177Lu]Lu-NYM096在透明细胞肾细胞癌中的临床前与首次人体研究

Preclinical and First-in-Human Study of Carbonic Anhydrase IX-Targeting Theranostic Pair, [68Ga]Ga/[177Lu]Lu-NYM096, in Clear Cell Renal Cell Carcinoma.
PubMed 文献 · J Nucl Med · 2026-09-02

该研究在OS-RC-2荷瘤小鼠中评估了[68Ga]Ga-NYM096的生物分布及[177Lu]Lu-NYM096(8.1-74 MBq)的疗效,并前瞻性纳入标准治疗进展的转移性ccRCC患者,进行系列[68Ga]Ga-NYM096 PET/CT及[177Lu]Lu-NYM096治疗(1.85 GBq起始,3+3剂量递增)。2例患者中[68Ga]Ga-NYM096 1小时SUVmax达330.0,治疗未见肾、肝、胰腺毒性,患者1出现1级胃部副作用和贫血,患者2发生3级放射性胃炎,随访PET/CT显示肿瘤响应。

要点

  • 临床前显示[177Lu]Lu-NYM096呈剂量依赖性肿瘤抑制且耐受良好。
  • 2例患者中[68Ga]Ga-NYM096 1小时SUVmax高达330.0,肿瘤摄取优异。
  • [177Lu]Lu-NYM096治疗未观察到肾毒性、肝毒性或胰腺毒性。

核心结论

  • CAIX靶向诊疗配对[68Ga]Ga/[177Lu]Lu-NYM096在终末期ccRCC患者中可行。
  • 胃毒性是CAIX靶向放射性药物治疗面临的显著挑战。

研究设计与样本

  • 临床前在OS-RC-2荷瘤小鼠中评估[68Ga]Ga-NYM096生物分布及[177Lu]Lu-NYM096(8.1-74 MBq)疗效。
  • 前瞻性纳入标准治疗进展的转移性ccRCC患者,行系列[68Ga]Ga-NYM096 PET/CT评估生物分布与剂量学。
  • CAIX表达阳性患者进入治疗阶段,接受[177Lu]Lu-NYM096,采用标准3+3剂量递增设计,起始剂量1.85 GBq。
  • 首次治疗周期后行系列全身平面成像,评估安全性、剂量学与初步疗效。

主要发现

  • OS-RC-2荷瘤小鼠中[68Ga]Ga/[177Lu]Lu-NYM096肿瘤摄取高,[177Lu]Lu-NYM096耐受良好且呈显著剂量依赖性肿瘤抑制。
  • 2例患者中[68Ga]Ga-NYM096注射后1小时SUVmax为330.0。
  • [177Lu]Lu-NYM096治疗未见肾毒性、肝毒性或胰腺毒性证据。
  • 患者1出现1级胃部副作用和贫血,患者2发生3级放射性胃炎。
  • 随访[68Ga]Ga-NYM096 PET/CT显示肿瘤对[177Lu]Lu-NYM096治疗有响应证据。

关键数值与推荐

  • 临床前[177Lu]Lu-NYM096治疗剂量递增范围为8.1至74 MBq。
  • 患者[177Lu]Lu-NYM096治疗采用标准3+3剂量递增设计,起始剂量为1.85 GBq。
  • 2例患者中[68Ga]Ga-NYM096注射后1小时SUVmax为330.0。

临床怎么用

  • 对标准治疗进展的转移性ccRCC患者,可考虑[68Ga]Ga-NYM096 PET/CT评估CAIX表达以筛选治疗候选者。
  • CAIX表达阳性者可按3+3剂量递增设计接受[177Lu]Lu-NYM096治疗,并密切监测胃毒性。

局限性

  • 首次人体研究仅纳入2例患者,样本量有限。
  • 胃毒性(包括3级放射性胃炎)构成CAIX靶向放射性药物治疗的显著挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Small-molecule PET tracers targeting carbonic anhydrase IX (CAIX) have recently been developed for patients with clear cell renal cell carcinoma (ccRCC). Here, we report the preclinical results and first-in-human study of a CAIX-targeting theranostic pair, [68Ga]Ga/[177Lu]Lu-NYM096, for patients with metastatic ccRCC, aiming to assess its safety, tolerability, dosimetry, and preliminary efficacy. Methods: The in vivo biodistribution of [68Ga]Ga-NYM096 was evaluated in mice bearing OS-RC-2 xenografts. The therapeutic efficacy of [177Lu]Lu-NYM096 was assessed with a dose escalating from 8.1 to 74 MBq. Patients with metastatic ccRCC who had disease progression after standard therapy were prospectively enrolled. Serial whole-body [68Ga]Ga-NYM096 PET/CT scans were performed to evaluate biodistribution and dosimetry. Patients with positive CAIX expression entered the therapeutic phase and received [177Lu]Lu-NYM096 following a standard 3-plus-3 dose escalation design that started from 1.85 GBq. Serial whole-body planar imaging was performed after the first therapy cycle. Safety, dosimetry, and preliminary efficacy were evaluated. Results: High tumor accumulation of [68Ga]Ga/[177Lu]Lu-NYM096 was observed in OS-RC-2 xenograft tumor models. Moreover, [177Lu]Lu-NYM096 was well tolerated and demonstrated a significant dose-dependent tumor suppression effect. In the 2 patients, [68Ga]Ga-NYM096 demonstrated excellent tumor uptake, with an SUVmax of 330.0 at 1 h postinjection. Subsequent [177Lu]Lu-NYM096 treatment demonstrated no evidence of nephrotoxicity, hepatotoxicity, or pancreatic toxicity. Patient 1 experienced grade 1 gastric side effects and anemia, whereas patient 2 developed grade 3 radiation-induced gastritis. Follow-up [68Ga]Ga-NYM096 PET/CT evaluations showed evidence of tumor response to [177Lu]Lu-NYM096 treatment. Conclusion: This is early evidence that the CAIX-targeting theranostic pair [68Ga]Ga/[177Lu]Lu-NYM096 is feasible, offering a strategy for patients with end-stage ccRCC. The gastric toxicity proposes a significant challenge for CAIX-targeting radiopharmaceutical therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wang J, Yan X, Liu M, et al. Preclinical and First-in-Human Study of Carbonic Anhydrase IX-Targeting Theranostic Pair, [68Ga]Ga/[177Lu]Lu-NYM096, in Clear Cell Renal Cell Carcinoma. J Nucl Med. 2026. PMID: 41991341. doi:10.2967/jnumed.125.271604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。